ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

GSK Gsk Plc

1,707.50
34.50 (2.06%)
Last Updated: 12:03:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Gsk Plc LSE:GSK London Ordinary Share GB00BN7SWP63 ORD 31 1/4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  34.50 2.06% 1,707.50 1,707.50 1,708.50 1,712.50 1,673.00 1,685.50 2,024,902 12:03:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 30.33B 4.93B 1.1970 14.22 70.09B
Gsk Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker GSK. The last closing price for Gsk was 1,673p. Over the last year, Gsk shares have traded in a share price range of 1,302.60p to 1,719.80p.

Gsk currently has 4,117,033,438 shares in issue. The market capitalisation of Gsk is £70.09 billion. Gsk has a price to earnings ratio (PE ratio) of 14.22.

Gsk Share Discussion Threads

Showing 13801 to 13825 of 33125 messages
Chat Pages: Latest  557  556  555  554  553  552  551  550  549  548  547  546  Older
DateSubjectAuthorDiscuss
15/2/2017
09:10
I'm still in my teens..😀
ny boy
14/2/2017
13:58
lol!!, believe me I take quite a bit of medication so very unlikely
to make old bones, so 40's are the new 60's for me.

essentialinvestor
14/2/2017
13:44
Wish I were still middle aged ES :-)
sicker
14/2/2017
13:33
Nope, you are not, tend to be a middle aged cynic these days but AW can be proud
of his efforts in access to medicines for poorer countries, GSK do more
than about any other pharma company in this area.

essentialinvestor
14/2/2017
13:29
Pity more directors would not replicate Andrew Witty's gift of shares in the aid of science. (hope I'm not spouting rubbish :-))
sicker
14/2/2017
10:51
Yes, that's much needed.

(Today ViiV Healthcare announced detailed positive phase III results for investigational two-drug regimen of dolutegravir and rilpivirine for HIV treatment)

tradermichael
14/2/2017
10:39
Michael, Gilead announced some positive data on their new HIV compound
yesterday, it's Phase 11, so needs to clear the larger phase 111 hurdle before they file.

Would expect ViiV will file for approval asap on today's news.

essentialinvestor
14/2/2017
10:36
updated:

14th feb Liberum buy tp 1900p
14th feb Shore Cap hold -
13th feb Jefferies buy tp 1780p
10th feb Berenberg buy tp 1850p
10th feb JP Morgan neutral tp 1670p
10th feb Beaufort buy tp 1750p
10th feb Deutsche hold tp 1720p


8th feb ++++ Q4 results ++++

philanderer
14/2/2017
09:51
I'll be buying some more when the next dividend comes in ..... ;0)
tradermichael
14/2/2017
09:50
Just out of bed :-)


... good update

philanderer
14/2/2017
09:44
x div next week, 23 February ..... ;0)
tradermichael
14/2/2017
09:00
Must be going ex divi soon

Happy with my holding from 1510p

ny boy
14/2/2017
08:15
Added a few under 15.65, the news was not unexpected as mentioned.
essentialinvestor
14/2/2017
07:36
Great news - glad I've been topping up at the lows.
woodhawk
14/2/2017
07:24
It is fantastic news, although not unexpected.

Have mentioned the two drug regime potential a number of times,
what it will hopefully do is take further share in this market.

There will be a cost saving benefit and a side effect profile benefit for
patients

With growing pressures on healthcare budgets it is a very welcome development.

essentialinvestor
14/2/2017
07:21
Yep, all good here, sitting on the throne reading the rns.

John C Pottage, Jr, MD, Chief Scientific and Medical Officer, ViiV Healthcare, commented, "The results from these studies may change our understanding of how HIV can be managed. For more than 20 years we thought that three or more drugs were required to maintain virologic suppression, but the SWORD studies provide compelling data that suppression may be maintained with a two drug regimen of dolutegravir and rilpivirine. These data mark an exciting first step towards making two drug regimens a reality in HIV treatment. We are planning regulatory submissions for this two-drug regimen as a single tablet in 2017."

ny boy
14/2/2017
07:18
Anybody alive???ViiV results in.
phatprofit
13/2/2017
09:02
13th feb Jefferies buy tp 1780p
10th feb JP Morgan neutral tp 1670p up from 1600p

philanderer
11/2/2017
09:46
Great. Thanks for posts.
philo124
11/2/2017
07:43
GSK ex div (again) in under 2 weeks ...... ;0)
tradermichael
10/2/2017
15:51
The pull back was a bear trap, soon we can break 1615p and head for 1700p
ny boy
10/2/2017
11:02
Yep, that`s what it was...

" UK Industrial Production Growth Tops Expectations "

philanderer
10/2/2017
10:45
Hmm could be pound related then.
tim 3
10/2/2017
09:55
Did they cut BATS too as the share price trace was pretty much identical to GSK
andyadvfn1
10/2/2017
09:48
See above cut came out at 9.10.
tim 3
Chat Pages: Latest  557  556  555  554  553  552  551  550  549  548  547  546  Older

Your Recent History

Delayed Upgrade Clock